Before 1997
The Puzzle of Psoriasis
A Question Hidden in Plain Sight
Key moment
100 million psoriasis patients worldwide — yet almost none get skin infections
Psoriasis affects over 100 million people worldwide. Their skin turns red, swollen, and covered in silvery scales. The outer layer of skin grows too fast, piling up in thick patches that crack and bleed.
By all logic, these patients should be constantly fighting skin infections. Their skin barrier is broken. Bacteria should pour in through every crack. Yet dermatologists had noticed something strange for decades: psoriasis patients almost never get bacterial skin infections.
Meanwhile, patients with eczema — another common skin disease — suffered the opposite problem. Their skin was constantly infected with staph bacteria, even though their skin looked less damaged than psoriasis patients. Nobody could explain why.
At the University of Kiel in northern Germany, Professor Enno Christophers kept asking his colleagues the same question: What is protecting psoriatic skin? Most shrugged it off. But a young researcher named Jürgen Harder decided to find out.
The Breakthrough
Mining for Gold in Skin Scales
A Discovery Published in Nature
Key moment
First antimicrobial peptide ever isolated from human skin
Harder's approach was unconventional. He collected the dry, flaky scales that psoriasis patients shed from their skin — material that most people would throw away. He ground up these scales, dissolved them, and ran the mixture through a series of filters designed to catch any molecule that could kill bacteria.
What he found made history. Hidden in those discarded skin flakes was a tiny protein — just 41 amino acids long — that killed bacteria on contact. When he tested it against common skin pathogens like E. coli and the yeast Candida, it wiped them out.
Harder and his mentor Schröder recognized the protein as a new member of the defensin family — nature's oldest group of antimicrobial peptides, found in everything from plants to insects to humans. They named it Human Beta-Defensin 2, or HBD-2.
The paper was published in Nature in 1997 with a simple but groundbreaking title: 'A peptide antibiotic from human skin.' It was the first time anyone had proven that human skin cells manufacture their own antibiotics.
The Trials
The Alarm System
A Weapon That Only Fires When Needed
Key moment
Eczema patients make far less HBD-2 — explaining their constant infections
What made HBD-2 truly remarkable was that healthy skin barely made it. Unlike HBD-1, which is always present at low levels, HBD-2 was an 'inducible' defensin — it only switched on when skin detected danger.
When bacteria touched skin cells, or when the immune system released alarm signals like TNF-alpha and interleukin-1, skin cells ramped up HBD-2 production dramatically. It was like an air raid siren that activated anti-aircraft guns.
Then came the breakthrough that connected everything. In 2002, Peck Ong published a landmark study in the New England Journal of Medicine. He compared defensin levels in psoriasis patients versus eczema patients. The results were stunning.
Psoriasis skin was flooded with HBD-2 and LL-37. Eczema skin made almost none. This finally explained the mystery: psoriasis patients were protected because their inflamed skin was pumping out natural antibiotics. Eczema patients were vulnerable because their alarm system was broken.
The Crisis
The Double-Edged Sword
When Protection Becomes the Problem
Key moment
Extra copies of the defensin gene increase psoriasis risk
As research deepened, scientists discovered a troubling side to the defensin story. In psoriasis, the immune system was making too much HBD-2 — and the peptide wasn't just killing bacteria. It was also calling in more immune cells, which caused more inflammation, which triggered even more HBD-2 production.
This created a vicious cycle. The very weapon that protected psoriasis patients from infections was also fueling the disease itself. Studies found that people with extra copies of the defensin gene were more likely to develop psoriasis in the first place.
Researchers also discovered that HBD-2 could attract immature immune cells called dendritic cells and memory T cells by hooking onto a sensor called CCR6. This meant HBD-2 wasn't just an antibiotic — it was a bridge between the body's fast-acting first defenses and its slower, more targeted immune response.
The challenge became clear: How do you harness HBD-2's bacteria-killing power without triggering unwanted inflammation?
The Legacy
Unlocking the Code
From Understanding to Application
Key moment
HBD-2 blood levels now used to track psoriasis severity
Today, HBD-2 research has branched into several exciting directions. Scientists are exploring whether boosting defensin production could help eczema patients fight off the staph infections that make their disease worse. Others are investigating synthetic versions of HBD-2 as alternatives to failing antibiotics.
One of the most promising discoveries is that HBD-2 doesn't just kill bacteria directly — it also protects the skin barrier from damage caused by bacterial toxins. Studies have shown that it blocks a bacterial weapon called V8 protease, which staph bacteria use to chew through skin proteins.
Researchers are also using HBD-2 levels as a biomarker — a measurable signal — to track how severe psoriasis is and whether treatments are working. Blood tests for HBD-2 could give doctors a simple way to monitor skin diseases without taking biopsies.
What started with a curious question about psoriasis has grown into one of the most important stories in skin science — proving that our largest organ is also one of our most active defenders.
Peptide history · 1997
Human Beta-Defensin 2
The Skin's Secret Antibiotic Hidden in Plain Sight
When dermatologists noticed that psoriasis patients almost never got skin infections — despite having raw, inflamed skin — they went looking for answers. What they found was a tiny natural antibiotic produced by skin cells themselves, rewriting everything we knew about how skin protects us.
Found in psoriatic skin scales
Mature peptide after processing
Daltons
Chromosome 8p23.1
Only made when skin detects danger
Compound classification
Dr. Jürgen Harder
The Skin Detective · University of Kiel, Germany
In 1997, Harder isolated the first antimicrobial peptide ever found in human skin — HBD-2 — by collecting the dry, flaky scales from psoriasis patients and grinding them up to search for bacteria-killing molecules. His paper in Nature proved that human skin makes its own antibiotics.
We wondered why psoriasis patients, with all that damaged skin, almost never got infections. The answer was hiding in the scales themselves.
Prof. Jens-Michael Schröder
The Architect of Skin Immunity · University of Kiel, Germany
Schröder led the Kiel research group that pioneered the study of skin antimicrobial peptides. His lab developed the methods to extract and identify HBD-2, and later discovered HBD-3. He showed that skin is an active immune organ, not just a passive barrier.
For centuries, we thought skin was just wrapping paper. It turns out it's one of the most sophisticated immune organs in the body.
Dr. Peck Y. Ong
The Eczema Connection · Children's Hospital Los Angeles / USC
In a landmark 2002 New England Journal of Medicine paper, Ong showed that people with eczema (atopic dermatitis) make far less HBD-2 than people with psoriasis. This explained why eczema patients get so many skin infections — their natural antibiotic production was turned down.
The difference was striking. Psoriasis patients flooded their skin with defensins. Eczema patients barely made any. That explained everything about their infection rates.
Prof. Enno Christophers
The Clinical Visionary · University of Kiel, Germany
Christophers was the senior dermatologist who first posed the puzzle that launched the discovery: Why do psoriasis patients — whose skin is red, cracked, and inflamed — rarely develop skin infections? His clinical observation became the starting point for an entirely new field.
The clinical observation was so simple that everyone had overlooked it. Sometimes the best science starts with the most obvious question.
12 milestones, 1991 – 2024.
- 1991First beta-defensin (Tracheal Antimicrobial Peptide) discovered in cow airways
- 1995HBD-1 discovered — the first human beta-defensin, always present at low levels
- 1997Harder isolates HBD-2 from psoriatic skin scales — published in Nature
- 1997DEFB4 gene mapped to chromosome 8p22-p23.1
- 1999HBD-2 shown to be 'inducible' — only made when bacteria or danger signals are present
- 2000HBD-2 discovered to attract immune cells through the CCR6 receptor
- 2001HBD-3 discovered by the same Kiel team — active against staph bacteria
- 2002Ong's NEJM paper reveals eczema patients make far less HBD-2 than psoriasis patients
- 2008High defensin gene copy number linked to psoriasis risk
- 2009HBD-2 validated as a blood biomarker for psoriasis disease activity
- 2021HBD-2 shown to protect skin from atopic dermatitis by blocking bacterial toxins
- 2024HBD-2 mRNA analysis used to differentiate psoriasis from eczema in skin biopsies
Imagine your skin as a castle wall. HBD-2 is like boiling oil that the defenders pour down on invading enemies — but only when the castle is under attack. Healthy skin keeps this weapon in reserve. Threatened skin unleashes it.
Molecular structure
- Amino Acids
- 41 (mature)
- Precursor Length
- 64 amino acids
- Molecular Weight
- ~4,328 Da
- Disulfide Bonds
- 3 (stabilize shape)
- Gene
- DEFB4A
- Chromosome
- 8p23.1
Protected by high HBD-2 levels
Vulnerable due to low HBD-2 production
Compared to psoriasis patients
First skin-derived antimicrobial peptide
Real stories, real lives
Rachel Petersen
I spent my entire childhood covered in staph infections. Every crack in my skin turned into a new battle. When I learned that my skin wasn't making enough of its own natural antibiotics — that my body's alarm system was turned down — it finally made sense. I wasn't unlucky. My skin's defense system was just wired differently.
Dr. Thomas Eriksson
When we measured HBD-2 in psoriasis patients versus eczema patients, the difference was like night and day. Psoriasis skin was flooding the surface with natural antibiotics. Eczema skin was barely making any. That one comparison explained decades of clinical mystery.
The future of Defensin (HBD-2)
- Eczema Defense BoostersPreclinical Research
Drugs that boost HBD-2 production in eczema patients to reduce their constant skin infections
- Synthetic Defensin AntibioticsEarly Research
Lab-made versions of HBD-2 designed to kill superbugs without triggering excessive inflammation
- Disease Activity BiomarkerClinical Validation
Simple blood tests measuring HBD-2 levels to track psoriasis severity without skin biopsies
- Wound Infection PreventionPreclinical
Topical HBD-2 creams to protect surgical wounds and burns from bacterial infection
Be inspired
The story of Defensin (HBD-2) is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.